|
1
|
Spira A and Ettinger DS: Multidisciplinary
management of lung cancer. N Engl J Med. 350:379–392. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Leon G, MacDonagh L, Finn SP, Cuffe S and
Barr MP: Cancer stem cells in drug resistant lung cancer: Targeting
cell surface markers and signaling pathways. Pharmacol Ther.
158:71–90. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Huang L and Fu L: Mechanisms of resistance
to EGFR tyrosine kinase inhibitors. Acta Pharm Sin B. 5:390–401.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kobayashi S, Boggon TJ, Dayaram T, Jänne
PA, Kocher O, Meyerson M, Johnson BE, Eck MJ, Tenen DG and Halmos
B: EGFR mutation and resistance of non-small-cell lung cancer to
gefitinib. N Engl J Med. 352:786–792. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Engelman JA, Zejnullahu K, Mitsudomi T,
Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen
J, et al: MET amplification leads to gefitinib resistance in lung
cancer by activating ERBB3 signaling. Science. 316:1039–1043. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Rho JK, Choi YJ, Kim SY, Kim TW, Choi EK,
Yoon SJ, Park BM, Park E, Bae JH, Choi CM and Lee JC: MET and AXL
inhibitor NPS-1034 exerts efficacy against lung cancer cells
resistant to EGFR kinase inhibitors because of MET or AXL
activation. Cancer Res. 74:253–262. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sequist LV, Waltman BA, Dias-Santagata D,
Digumarthy S, Turke AB, Fidias P, Bergethon K, Shaw AT, Gettinger
S, Cosper AK, et al: Genotypic and histological evolution of lung
cancers acquiring resistance to EGFR inhibitors. Sci Transl Med.
3:75ra262011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
MacDonagh L, Gray SG, Breen E, Cuffe S,
Finn SP, O'Byrne KJ and Barr MP: Lung cancer stem cells: The root
of resistance. Cancer Lett. 372:147–156. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Loh YH, Wu Q, Chew JL, Vega VB, Zhang W,
Chen X, Bourque G, George J, Leong B, Liu J, et al: The Oct4 and
Nanog transcription network regulates pluripotency in mouse
embryonic stem cells. Nat Genet. 38:431–440. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wang Z, Oron E, Nelson B, Razis S and
Ivanova N: Distinct lineage specification roles for NANOG, OCT4,
and SOX2 in human embryonic stem cells. Cell Stem Cell. 10:440–454.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Cai L, Ye Z, Zhou BY, Mali P, Zhou C and
Cheng L: Promoting human embryonic stem cell renewal or
differentiation by modulating Wnt signal and culture conditions.
Cell Res. 17:62–72. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lazarevic M, Milosevic M, Trisic D, Toljic
B, Simonovic J, Nikolic N, Mikovic N, Jelovac D, Petrovic M,
Vukadinovic M and Milasin J: Putative cancer stem cells are present
in surgical margins of oral squamous cell carcinoma. J BUON.
23:1686–1692. 2018.PubMed/NCBI
|
|
13
|
Milosevic M, Lazarevic M, Toljic B,
Simonovic J, Trisic D, Nikolic N, Petrovic M and Milasin J:
Characterization of stem-like cancer cells in basal cell carcinoma
and its surgical margins. Exp Dermatol. 27:1160–1165. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Tan CS, Gilligan D and Pacey S: Treatment
approaches for EGFR-inhibitor-resistant patients with
non-small-cell lung cancer. Lancet Oncol. 16:e447–e459. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cho BC, Chewaskulyong B, Lee KH,
Dechaphunkul A, Sriuranpong V, Imamura F, Nogami N, Kurata T,
Okamoto I, Zhou C, et al: Osimertinib versus standard of care EGFR
TKI as first-line treatment in patients with EGFRm advanced NSCLC:
FLAURA asian subset. J Thorac Oncol. 14:99–106. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kelly RJ, Shepherd FA, Krivoshik A, Jie F
and Horn L: A phase 3, randomized, open-label study of asp8273
versus erlotinib or gefitinib in patients with advanced stage
iiib/iv non-small cell lung cancer. Ann Oncol. 30:1127–1133. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Cha YK, Lee HY, Ahn MJ, Choi YL, Lee JH,
Park K and Lee KS: Survival outcome assessed according to tumor
burden and progression patterns in patients with epidermal growth
factor receptor mutant lung adenocarcinoma undergoing epidermal
growth factor receptor tyrosine kinase inhibitor therapy. Clin Lung
Cancer. 16:228–236. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Gu D, Su S, Ge D, Chen S, Huang J, Li B,
Chen R and Qiang B: Association study with 33 single-nucleotide
polymorphisms in 11 candidate genes for hypertension in Chinese.
Hypertension. 47:1147–1154. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
McClelland RA, Finlay P, Walker KJ,
Nicholson D, Robertson JF, Blamey RW and Nicholson I: Automated
quantitation of immunocytochemically localized estrogen receptors
in human breast cancer. Cancer Res. 50:3545–3550. 1990.PubMed/NCBI
|
|
20
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
statistics, 2010. CA: Cancer J Clin. 60:277–300. 2010.PubMed/NCBI
|
|
22
|
Cojoc M, Mabert K, Muders MH and Dubrovska
A: A role for cancer stem cells in therapy resistance: Cellular and
molecular mechanisms. Semin Cancer Biol. 31:16–27. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Nakatsugawa M, Takahashi A, Hirohashi Y,
Torigoe T, Inoda S, Murase M, Asanuma H, Tamura Y, Morita R,
Michifuri Y, et al: SOX2 is overexpressed in stem-like cells of
human lung adenocarcinoma and augments the tumorigenicity. Lab
Invest. 91:1796–1804. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhang X, Hu F, Li C, Zheng X, Zhang B,
Wang H, Tao G, Xu J, Zhang Y and Han B: OCT4&SOX2-specific
cytotoxic T lymphocytes plus programmed cell death protein 1
inhibitor presented with synergistic effect on killing lung cancer
stem-like cells in vitro and treating drug-resistant lung cancer
mice in vivo. J Cell Physiol. 234:6758–6768. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Rousseaux S, Debernardi A, Jacquiau B,
Vitte AL, Vesin A, Nagy-Mignotte H, Moro-Sibilot D, Brichon PY,
Lantuejoul S, Hainaut P, et al: Ectopic activation of germline and
placental genes identifies aggressive metastasis-prone lung
cancers. Sci Transl Med. 5:186ra662013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Sharma SV, Lee DY, Li B, Quinlan MP,
Takahashi F, Maheswaran S, McDermott U, Azizian N, Zou L, Fischbach
MA, et al: A chromatin-mediated reversible drug-tolerant state in
cancer cell subpopulations. Cell. 141:69–80. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chiou SH, Wang ML, Chou YT, Chen CJ, Hong
CF, Hsieh WJ, Chang HT, Chen YS, Lin TW, Hsu HS and Wu CW:
Coexpression of Oct4 and Nanog enhances malignancy in lung
adenocarcinoma by inducing cancer stem cell-like properties and
epithelial-mesenchymal transdifferentiation. Cancer Res.
70:10433–10444. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Shien K, Toyooka S, Yamamoto H, Soh J,
Jida M, Thu KL, Hashida S, Maki Y, Ichihara E, Asano H, et al:
Acquired resistance to EGFR inhibitors is associated with a
manifestation of stem cell-like properties in cancer cells. Cancer
Res. 73:3051–3061. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hassan KA, Chen G, Kalemkerian GP, Wicha
MS and Beer DG: An embryonic stem cell-like signature identifies
poorly differentiated lung adenocarcinoma but not squamous cell
carcinoma. Clin Cancer Res. 15:6386–6390. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhang Y, Kang S, Fang W, Hong S, Liang W,
Yan Y, Qin T, Tang Y, Sheng J and Zhang L: Impact of smoking status
on EGFR-TKI efficacy for advanced non-small-cell lung cancer in
EGFR mutants: A meta-analysis. Clin Lung Cancer. 16:144–51.e1.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hasegawa Y, Ando M, Maemondo M, Yamamoto
S, Isa S, Saka H, Kubo A, Kawaguchi T, Takada M, Rosell R, et al:
The role of smoking status on the progression-free survival of
non-small cell lung cancer patients harboring activating epidermal
growth factor receptor (EGFR) mutations receiving first-line EGFR
tyrosine kinase inhibitor versus platinum doublet chemotherapy: A
meta-analysis of prospective randomized trials. Oncologist.
20:307–315. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Bria E, Milella M, Cuppone F, Novello S,
Ceribelli A, Vaccaro V, Sperduti I, Gelibter A, Scagliotti GV,
Cognetti and Giannarelli D: Outcome of advanced NSCLC patients
harboring sensitizing EGFR mutations randomized to EGFR tyrosine
kinase inhibitors or chemotherapy as first-line treatment: A
meta-analysis. Ann Oncol. 22:2277–2285. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhou J and Ben S: Comparison of
therapeutic effects of EGFR-tyrosine kinase inhibitors on 19Del and
L858R mutations in advanced lung adenocarcinoma and effect on
cellular immune function. Thoracic Cancer. 9:228–233. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lee CK, Wu YL, Ding PN, Lord SJ, Inoue A,
Zhou C, Mitsudomi T, Rosell R, Pavlakis N, Links M, et al: Impact
of specific epidermal growth factor receptor (egfr) mutations and
clinical characteristics on outcomes after treatment with egfr
tyrosine kinase inhibitors versus chemotherapy in egfr-mutant lung
cancer: A meta-analysis. J Clin Oncol. 33:1958–1965. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Li X, Wang J, Xu Z, Ahmad A, Li E, Wang Y,
Qin S and Wang Q: Expression of Sox2 and Oct4 and their clinical
significance in human non-small-cell lung cancer. Int J Mol Sci.
13:7663–7675. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wu Y, Du X, Xue C, Li D, Zheng Q, Li X and
Chen H: Quantification of serum SOX2 DNA with FQ-PCR potentially
provides a diagnostic biomarker for lung cancer. Med Oncol.
30:7372013. View Article : Google Scholar : PubMed/NCBI
|
